crown

Subscribe Now

FOLLOW US

Sign in

Covaxin

Forget those vaccine fears, time to move on

The only appropriate way to interpret these numbers is to compare them with the rates for non-vaccinated populations with similar characteristics.(Getty Images/iStockphoto)

Published 772 days ago

‘Working to improve research ecosystem’: BHU conveys regret

File photo of Banaras Hindu University. (HT Archive)

Updated 783 days ago

ICMR distances itself from safety study on Covaxin

ICMR collaborated with Bharat Biotech on developing the inactivated vaccine. (Pratham Gokhale/HT Photo)

Updated 784 days ago

Covaxin study: Amid concern of adverse events, should vaccine takers be worried?

Serious AESI, including stroke and Guillain-Barre syndrome, were reported in around one per cent of individuals as per the study.

Published 787 days ago

1 in 3 Covaxin takers reported adverse events, BHU study claims

India's vaccination drive was largely powered by two vaccines — Covaxin and Covishield.

Published 788 days ago

VIEW ALL STORIES

Photos

Photos: India begins its Covid-19 vaccination drive

Photos: India begins its Covid-19 vaccination drive

Photos: India’s Covid-19 vaccines arrive in cities ahead of inoculation drive

Photos: India’s Covid-19 vaccines arrive in cities ahead of inoculation drive

VIEW ALL PHOTOS

Videos

Boost for Covaxin: After WHO nod, Lancet study says vaccine 77.8% effective

Boost for Covaxin: After WHO nod, Lancet study says vaccine 77.8% effective 

Covaxin gets WHO emergency nod; 'Atmanirbhar Diwali' says Mansukh Mandaviya

Covaxin gets WHO emergency nod; 'Atmanirbhar Diwali' says Mansukh Mandaviya

Covaxin effectively neutralises Delta Plus variant of Covid-19: New ICMR Study

Covaxin effectively neutralises Delta Plus variant of Covid-19: New ICMR Study

Covaxin good & bad news: US agency acclaim; Brazil deal suspension for probe

Covaxin good & bad news: US agency acclaim; Brazil deal suspension for probe

Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know | Covid

Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know | Covid

VIEW ALL VIDEOS

Home / Topic / Covaxin

© 2026 HindustanTimes